These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1416573)

  • 21. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.
    Lombardi G; Colao A; Marzullo P; Biondi B; Palmieri E; Fazio S;
    J Endocrinol Invest; 2002 Dec; 25(11):971-6. PubMed ID: 12553557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort.
    dos Santos Silva CM; Gottlieb I; Volschan I; Kasuki L; Warszawski L; Balarini Lima GA; Xavier SS; Pedrosa RC; Neto LV; Gadelha MR
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4447-55. PubMed ID: 26431508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.
    Merola B; Cittadini A; Colao A; Ferone D; Fazio S; Sabatini D; Biondi B; Saccá L; Lombardi G
    J Clin Endocrinol Metab; 1993 Sep; 77(3):790-3. PubMed ID: 8370700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion.
    Lefebvre S; De Paepe L; Abs R; Rahier J; Selvais P; Maiter D
    Eur J Endocrinol; 1995 Sep; 133(3):320-4. PubMed ID: 7581949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CLINICAL, BIOCHEMICAL AND HORMONAL PREDICTORS OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ACROMEGALY].
    Mykytyuk MR
    Lik Sprava; 2015; (5-6):34-40. PubMed ID: 27089713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High affinity growth hormone binding protein in plasma of patients with acromegaly and the effect of octreotide treatment.
    Roelen CA; Donker GH; Thijssen JH; Koppeschaar HP; Blankenstein MA
    Clin Endocrinol (Oxf); 1992 Oct; 37(4):373-8. PubMed ID: 1483295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy.
    Manelli F; Desenzani P; Boni E; Bugari G; Negrini F; Romanelli G; Grassi V; Giustina A
    Pituitary; 1999 Nov; 2(3):205-10. PubMed ID: 11081155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular consequences of early-onset growth hormone excess.
    Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor.
    Melmed S; Ziel FH; Braunstein GD; Downs T; Frohman LA
    J Clin Endocrinol Metab; 1988 Aug; 67(2):395-9. PubMed ID: 2899089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass.
    Vitale G; Galderisi M; Pivonello R; Spinelli L; Ciccarelli A; de Divitiis O; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):343-9. PubMed ID: 15009000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.